Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay

Peptide mobility shift assays provide a sensitive measure of kinase enzymatic activity and can be used to evaluate kinase inhibitors. Herein, we describe a protocol adapted for rapid assessment of doublecortin-like kinase inhibitors. Advantages include rapid iterations of therapeutic compound assessment and the ability to characterize kinase mutations, such as drug-resistant mutants for biological rescue experiments, on kinase activity. For complete details on the use and execution of this protocol, please refer to Liu et al. (2020).